The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia
Open accessAbstract
In recent years, the metabotropic glutamate (mGlu) receptors have emerged as potential new drug targets for treatment of a range of CNS disorders. Some of the most compelling advances have been made in targeting specific mGlu receptor subtypes as a fundamentally new approach to the treatment of schizophrenia. Recent animal and clinical studies provide strong evidence that agonists of group II mGlu receptors (mGluR2 and mGluR3) are effective in the treatment of the positive symptoms of schizophrenia, and animal studies suggest that mGluR5 agonists could provide a novel approach for the treatment of all major symptom domains (positive, negative, and cognitive) of this disorder. Although the discovery of selective agonists of these receptors is a challenge, there have been recent advances in the discovery of highly selective positive allosteric modulators (PAMs) of mGluR2 and mGluR5. These mGlu receptor-selective PAMs have properties needed for optimization as clinical candidates and have robust effects in animal models that predict efficacy in treatment of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J.-P. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,081
Self-citationMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Self-citationPatil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Lu, Y.-M., Jia, Z., Janus, C., Henderson, J. T., Gerlai, R., Wojtowicz, J. M., & Roder, J. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-13-05196.1997 · Cited by 634
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529
Metabotropic Glutamate Receptors 1 and 5 Differentially Regulate CA1 Pyramidal Cell Function
Mannaioni, G., Marino, M. J., Valenti, O., Traynelis, S. F., & Conn, P. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-05925.2001 · Cited by 441
Self-citation
Cited by
Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease
Niswender, C. M., & Conn, P. J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145533 · Cited by 1,892
Self-citationMoghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Metabotropic glutamate receptors: From the workbench to the bedside
Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., Wroblewski, J. T., & Pin, J. P. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.022 · Cited by 653
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Kenakin, T., & Miller, L. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.108.000992 · Cited by 573
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Goriounova, N. A., & Mansvelder, H. D. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a012120 · Cited by 307
“Activation of this receptor has even been proposed as a novel treatment approach for these disorders (Gupta et al. 2005; Palucha and Pilc 2005; Pilc et al. 2008; Conn et al. 2009).”
BackgroundComparative genomics of autism and schizophrenia
Crespi, B., Stead, P., & Elliot, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906080106 · Cited by 262
Role of BDNF epigenetics in activity-dependent neuronal plasticity
Karpova, N. N. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.002 · Cited by 200
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
Caprioli, D., Venniro, M., Zeric, T., Li, X., Adhikary, S., Madangopal, R., Marchant, N. J., Lucantonio, F., Schoenbaum, G., Bossert, J. M., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.018 · Cited by 145
Goriounova, N. A., & Mansvelder, H. D. (2012) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2012.00003 · Cited by 65
Goriounova, N. A., & Mansvelder, H. D. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5502-11.2012 · Cited by 51
Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders
Engers, D. W., & Lindsley, C. W. (2013) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2012.10.007 · Cited by 45
Self-citationAugier, E., Dulman, R. S., Rauffenbart, C., Augier, G., Cross, A. J., & Heilig, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.107 · Cited by 44
Advancing drug discovery for schizophrenia
Marder, S. R., Roth, B., Sullivan, P. F., Scolnick, E. M., Nestler, E. J., Geyer, M. A., Welnberger, D. R., Karayiorgou, M., Guidotti, A., Gingrich, J., et al. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06216.x · Cited by 25
Self-citation
Metadata
- Authors
- Conn, P. J., Lindsley, C. W., & Jones, C. K.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 30
- Issue
- 1
- Pages
- 25-31
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2065940220
- Cited by
- 330
- References
- 65
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.